Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

A new RSV shot for infants is in short supply

A new shot for infants against RSV is in short supply, and U.S. health officials are telling doctors they should prioritize giving the drug to babies at the highest risk of severe disease

The Independent UK

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Investors Business Daily

Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Surges After Flu Shot Beats Out Widely Used Sanofi, GSK Vaccines

Moderna said Wednesday its flu shot outperformed broadly used vaccines from Sanofi and GSK. The results bolstered Moderna stock.

Investors Business Daily

3 Pharma Stocks to Buy Now for a Dose of Profit

The pharmaceutical sector is expanding due to advanced technologies such as AI and new drug discoveries. Hence, quality pharma stocks GoodRx Holdings (GDRX), Merck & Co. (MRK), and Sanofi (SNY) might be profitable investments right now. Read on.

StockNews.com

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

StockNews.com

New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season

U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

The Guardian - UK

Gary Vee, Kevin Durant, Alex Rodriguez Backed Tracer Land New Investors

Data intelligence platform, Tracer, announced a new president to lead the company

Zenger

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Investors Business Daily

Gen Z needs brand-new skills to climb to the C-suite, says healthcare CEO

Knowing how to use and implement generative A.I. will be a “minimum expectation” for future CEOs, Sanofi CEO Paul Hudson said.

Fortune

U.S. firm StemCures to set up manufacturing lab in Telangana

StemCures, a medical clinic in Ohio focused on stem cell therapy, will be establishing a manufacturing lab in Telangana with around $54 million investment and employment potential for around 150 people.

The Hindu

Sanofi CEO: ‘Europe’s lead in life sciences R&D is eroding–but co-localized hubs could allow it to keep up’

'Innovation is powered by more than just money,' writes Sanofi CEO Paul Hudson.

Fortune

Positive trial results for RSV infant treatment: Sanofi

Paris (AFP) - French pharmaceutical giant Sanofi announced trial results on Friday that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalised by more than 80 percent.

AFP

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns

Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. But Sanofi stock dipped Friday.

Evening Standard

Autumn Covid booster 2023: Who is eligible for another jab?

If invited, you will receive a booster dose of a Covid-19 vaccine made by Pfizer, Moderna, or Sanofi

The Week

Sanofi: the new protein-based Covid vaccine to be used in the UK

The University of Edinburgh’s Neil Mabbott on the vaccine technology being used for Covid booster jabs from this month.

Wales Online

Everything we know about new Sanofi Covid vaccine now being used in UK

The vaccine being used in the Spring booster campaign works in a different way to previous jabs

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Sanofi vaccine: what to know about this protein-based COVID booster being offered in the UK

In the UK a spring booster campaign has recently begun, offering an additional vaccine to people at highest risk from COVID. Between April and June 2023 people aged over 75, residents in care homes and children and adults aged five and up with weakened immune systems will be invited to…

Investors Business Daily

Stock Market Ekes Out Gains Across Major Indexes; Deutsche Bank Pares Losses

The stock market major indexes posted weekly gains despite a volatile week. Surgical robotic company gaps up on analyst coverage news.

Investors Business Daily

Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket.

Los Angeles Times

Newsom announces $50 million contract to make California’s own brand of insulin

LOS ANGELES — California Gov. Gavin Newsom announced a new $50-million contract with the nonprofit generic drugmaker Civica to produce insulin under the state’s own label during a news conference Saturday in Downey.

AFP

Sanofi, joining other drug makers, slashes US insulin price

New York (AFP) - French pharmaceutical giant Sanofi announced on Thursday it would cut the US price of its most prescribed insulin by 78 percent, falling in line with two other major drug makers.

Los Angeles Times

Michael Hiltzik: Eli Lilly is slashing insulin prices, but hold your applause

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

Axios

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.